Category Archives: Richard Wolf


KeyPort – The reusable Single Port solution from von Richard Wolf

It also offers users decisive benefits such as:

an exceptional level of surgical freedom
a modular setup
and instruments with universal application



ENDOCAM® Logic HD is the logical advanced development of existing camera systems from Richard Wolf. Sophisticated development processes and the exceptional expertise within the company have created a product that leaves nothing to be desired.


Shark -The new resectoscopes from Richard Wolf

Richard Wolf resectoscopes for urology have formed a platform for therapeutic and diagnostic interventions at the highest level for many decades. The new “Shark” resectoscope line now takes quality, comfort, control and safety to a new dimension. “Shark” combines global experience and user feedback over many years with innovative technology.

See for yourself.


(Compatible With Richard Wolf Working Element-24 FR. SHEATH
Single Steam Cutting Loop NSCL-WC
Single Steam Cold Knife NSCK-WC
Single Steam Kollins Knife NSKLK-WC
Single Steam Roller Electrode (3mm) NSRE-3-WC
Single Steam Roller Electrode (5mm) NSRE-5-WC
Single Steam Ball Electrode (3mm) NSRE-3-WC
Single Steam Ball Electrode (5mm) NSRE-5-WC
Working Element – 12 ( 26 FR. SHEATH )
Single Steam Cutting Loop NSCL-OC-12
Single Steam Cold Knife NSCK-OC
Single Steam Kollins Knife NSKLK-OC
Single Steam Roller Electrode (3mm) NSRE-3-OC
Single Steam Roller Electrode (5mm) NSRE-5-OC
Compatible with Olympus Working Element – 30 0 ( 26 FR. SHEATH
Single Steam Cutting Loop NSCL-OC-30

Wolf Endoscopy

Welcome to the Medical Specialties Blog on! If you have seen those commercials with the big red -easy button- and wish you had one for shopping online, you have come to the right place. Our fully optimized search engine is as close as you will ever get to an easy button and we just know you are going to love it.
Here is how you use it. At the top of this page you will see the little search box and all you must do is put your product or keyword search term in it and hit the button. Our technology is powerful and will search the Internet for results to bring back to you. Even though the box is small it can find clothes, appliances, toys, hunting gear, and almost anything else you can think of.
Medical Specialties Blog on wants to make all your shopping fun, easy, and a time saving event. Many times you can even buy food online! Shopping online means more time left over for you to spend with your loved ones instead of going from store to store, taking up all your spare time. Try it, test us out. The search box is waiting for you to give it a job to do.

Booty mining medical devices market to be worth $9.7 billion by 2016

Yes, endoscopy devices are really useful. Less invasive than traditional surgical procedures, and with the addition of more things like 3D cameras, they will turn you inside and out. There’s a lot of hidden financial booty for companies working their way up your booty.

Okay, we are still 12 years old when it comes to butt jokes, and we are not going to put up any more pictures of endoscopy devices at work and play. This is serious stuff. We are just jealous because there are billions of dollars to be had making cameras that get all up in there and that.

According to MarketsandMarkets, touting its Endoscopy Devices Market by Product [Rigid/Flexible Endoscopes, Visualization Systems, Endoscopic Ultrasounds], Application [Gastrointestinal, Laparoscopy, Arthroscopy] & Technology [Narrow Band Imaging, Capsule Endoscopy, Notes] – Global Forecasts To 2016:

The global healthcare industry has seen a shift in paradigm and is now skewed toward less-invasive therapies that not only cures serious illnesses, but also have fewer serious side effects. Demand for endoscopy has increased manifolds over the past decade owing to patient preference for minimally invasive surgeries.

The global endoscopy devices market was valued at $6.1 billion in the year 2011 and is expected to be $9.7 billion in the year 2016. North America was the largest endoscopy devices market, followed by Europe and Japan (2011). In the next five years, Asian countries are slated to register a maximum CAGR of 14.42% owing to increased healthcare spending by the government, healthcare reforms and increased patient awareness about minimally invasive surgeries (MIS).

Global endoscopy market is broadly segmented into the following product categories; rigid endoscopes, flexible endoscopes, endoscopy visualization systems, endoscopic ultrasounds, endoscopy fluid management systems, and endoscope accessories. Introduction of new, but expensive technologies such as HD cameras, 3DHD systems, HDTV three-chip systems, Narrow Band Imaging, Capsule Endoscopy, Natural Orifice Transluminal Endoscopic Surgery (NOTES), Picture Archiving and Communication Systems (PACS), Mucosal Ablation Therapy, Robotic Endoscopes etc. are expected to drive the global endoscopy market for the coming five years.

The global endoscopy devices market witnesses’ high competitive intensity as there are many big as well small firms with similar product offerings. The market is dominated by Olympus Corporation with 70% market share, in 2011. Hoya Corporation (Pentax Medical System), Fujifilm Holding Corporation, Karl Storz, Boston Scientific, Stryker, Richard Wolf, Smith and Nephew Inc., Johnson and Johnson-Ethicon Endo Surgery (EES), Given Imaging Ltd., ConMed etc. are some of the prominent players in the global endoscopy market.

Dammit Wolf, I’m a Doctor Not a Rational Person

Rep. Paul Broun of Georgia, one of the most far-right House members who is now running for the Senate, went on CNN and told Wolf Blitzer that Obamacare would “destroy everything we know as a nation.” And you know he’s right because, dammit Jim, he’s a doctor.
In an interview with CNN, Rep. Paul Broun (R-GA) told host Wolf Blitzer that he supported the government shutdown if it would help put an end to what he called “the flaw of the land.”
“We need to defund it, we need to delay it, we need to put it on the shelf and stop this implementation because it is destroying our economy,” he opined…
“Well, Obamacare must go,” Broun replied. “It’s destroying America…. Wolf, I want to get the American people the relief that they need from this out-of-control spending, and I’ll do everything that I possibly can do to do that.”
“And Obamacare is going to destroy everything we know as a nation,” he added. “Wolf, I’m a doctor. I’m a medical doctor!”
Which has precisely nothing to do with anything. Being a doctor doesn’t make him an expert on the economics of health care or on the functioning of insurance markets. This is an appeal to irrelevant authority. Broun loves to throw his medical degree around in defense of utterly moronic claims, like when he said that evolution and the big bang theory are “lies from the pit of hell.”


Complications should be less using a laparoscopic approach to hysterectomy. Laparoscopic hysterectomy (LH), defined as the laparoscopic dissection, ligation, and division of the uterine blood supply, is an alternative to abdominal hysterectomy with more attention to ureteral identification.1-3 First done in January, 1988,4 laparoscopic hysterectomy stimulated a general interest in the laparoscopic approach to hysterectomy as gynecologists not trained in vaginal or laparoscopic techniques struggled to maintain their share of the large lucrative hysterectomy market. A watered down version of LH called LAVH (laparoscopic assisted vaginal hysterectomy) was taught by industry and became known as an expensive over-utilized procedure with indications for which skilled vaginal surgeons rarely found the laparoscope necessary.

LH remains a reasonable substitute for abdominal hysterectomy. Laparoscopically assisted hysterectomy is a cost-effective procedure when done with reusable instruments; it is a safe procedure, even when performed by a variety of gynecologists with different skill levels, and its adoption can decrease abdominal incision hysterectomies.5
A laparoscopic hysterectomy is not indicated when vaginal hysterectomy is possible, i.e., when the uterine vessels are readily accessible vaginally. Most hysterectomies currently requiring an abdominal approach instead of vaginal surgery may be done with laparoscopic dissection of part, or all, of the abdominal portion followed by vaginal removal of the specimen. There are many surgical advantages to laparoscopy, particularly magnification of anatomy and pathology, access to the uterine vessels, vagina and rectum, and the ability to achieve complete hemostasis and clot evacuation. Patient advantages are multiple and are related to avoidance of a painful abdominal incision. They include reduced duration of hospitalization and recuperation and an extremely low rate of infection and ileus.

The goal of vaginal hysterectomy, LAVH, or LH, is to safely avoid an abdominal wall incision. The surgeon must remember that if he/she is more comfortable with vaginal hysterectomy after ligating the ovarian or utero-ovarian vessels, this should be done if possible. Laparoscopic inspection at the end of the procedure will still permit the surgeon to control any bleeding and evacuate clots, and laparoscopic cuff suspension can be done to limit future cuff prolapse.

Patient safety is the surgeon’s primary responsibility. Thus “learning curve” injury must be minimized. Unnecessary surgical procedures should not be done because of the surgeon’s preoccupation with the development of new surgical skills. Complications are an inevitable by-product of any surgical procedure, but everything possible must be done to reduce this risk. Obviously, the surgeon requires a strong background in operative laparoscopy and sufficient training to demonstrate proficiency.

The operative environment must be prepared for laparoscopic hysterectomy. Equipment must be available, functional, and a backup plan in place to cover any unanticipated malfunction. Additionally, and of equal importance, is the competence level of the operative team. Anesthesia, nursing, and the surgeon must share the same operative goals and actively cooperate to achieve them. Frequently neglected is the need for education of the postoperative support staff.

Reduction of risk begins with a detailed patient history and comprehensive physical examination, frequently including ultrasonographic confirmation of physical findings. Medical clearance is sought on anyone with any historical or physical suggestion that could lead to possible operative compromise. Since, in most cases hysterectomy is an elective procedure, the patient is counseled extensively regarding the range of currently available options appropriate to her individual clinical situation. In 1997 it is clearly not acceptable to advocate hysterectomy without detailing the risks/benefits of other intermediary procedures.

Since 1987, in my first 5 years experience with LH, no patient was denied a vaginal or laparoscopic approach to hysterectomy except when advanced cancer was suspected. As my practice is largely referral, this represents a significant degree of pathology. Only 9 of my first 123 women had benign pathology; in these cases hysterectomy was done for pelvic adhesions, and/or persistent hypermenorrhea. Laparotomy was not needed regardless of size or location of uterine fibroids or extent of endometriosis. Only one woman with extensive bowel adhesions and endometrial cancer underwent laparotomy to complete the hysterectomy and to reinforce four small bowel enterotomy repairs. This supported my belief that most hysterectomies presently performed with the abdominal approach could be done laparoscopically.

While conversion to laparotomy when the surgeon becomes uncomfortable with the laparoscopic approach should never be considered a complication, conversion rates should be monitored to safeguard the consumer’s right to have this procedure performed by a competent laparoscopic surgeon. Surgeons who do over 25% of their hysterectomies with an abdominal incision should not stretch their ability and degree of expertise with a laparoscopic approach to their patients.

Globus and Atlas Shrugged and Shrugged and Shrugged

Poor Atlas, the Titan giant has been burdened with holding up Globus’ spirits as the company attempts to finalize its initial public offering. “Oy vey,” Atlas is going to get tired from carrying Globus’ around during this dog and pony show. With all the hoopla surrounding a potential IPO, it seems Globus had to put the brakes on its original intent, so that it could up the ante from $100 million to $150 million. Hopefully the consultants from the Great Vampire Squid, Piper Jaffray, BOFA, et al will fare better than the genius’ at Morgan Stanley that led the Face-broke sham. Price this right and you will attract investors, get greedy and the repercussions will come back and bite you in the ass. Think Alpha Wreck. Considering that investor confidence is at an all time low in light of the recent Facebroke fiasco it will be interesting to evaluate how the Globus IPO plays out. If one takes the time out to read the preliminaries in the S-1 filing, Globus has done a nice job in managing its finances when it comes down to running a company. Of course those that have become collateral damage during the process will say otherwise. But the reality is that at this juncture its all about the financial data that counts. If anyone wonders why the Street sunk its teeth into medical devices look no further. In what other industry can a company generate on average 81% gross margins across the board? Containing COGS at 19% speaks volumes about production efficiencies at Globus. In addition, Globus has been able to stabilize their SG&A costs at 42% over the last few years, a sign that it has moved away from total independent distribution model. TSB anticipates that the SG&A will eventually come down a few points based on the current cost containment environment in medical devices. Like everything else what goes up must come down. So the question must be asked, why does Globus need another $50 million? Could they be anticipating potential litigation settlements with other companies? Let’s face it, based on this company’s track record, anything is possible. Choir Boys they ain’t, but then again they’re not running a church or mission are they?

On the surface Globus has a pretty good war chest considering it generated $331.5 million in sales with profits north of $60 million. Globus brags that they hold the title as the fastest growing company in the industry, but I bet the Purple People Eaters would beg to differ. The concern that TSB has regarding Globus is whether they are perceived as an innovator, or are they really nothing more than an imitator on steroids? As NBA players love to say, “no question” Globus makes beautiful instruments and understands the value that visual appearances make when selling a system. Yet, TSB must ask our readers, what has the competition attempted to copy from Globus’ portfolio? How about informing John Q. Public, a potential investor, about the scope of these 5-10 projects that you intend on marketing over the next three years. Mystique Smishtique. There should be some transparency if you want the dow. Please, spare us the standard line that this information is proprietary. One has to wonder, what makes this company so unique outside of being managed well? Is there one product in their portfolio that is a game breaker? We would love to see the number of surgeon investors and consultants that have effected tremendous growth at Globus because without their exuberance Globus CAGR wouldn’t be anywhere near where it plays. Will they run, or will they stay after the IPO? Will everyone have reaped a windfall?

When Globus reaches their IPO milestone, how many shares of Common A will they be offering and at what price? TSB wants to know what our readers think?

As Henry Butler sings on the latest Jeff Golub album,

Hey tell everybody TSB’s back in town, I got a dollar and a quarter just rarin’ to clown
But don’t let nobody play me cheap, I got fifty cents more that I’m going to keep, so
Let the Good Times Roll, I don’t care if you’re young or old, Let the Good Times Roll!

Single Port Laparoscopy for Ischaemic Small Bowel secondary to Acute Arterial Embolus

his video demonstrates a single port laparoscopy in a elderly patient presenting with an acute abdomen secondary to a gangrenous loop of ileum. The patient …

London (PRWEB) September 25, 2013

This report analyzes the worldwide markets for Endoscopy Systems in US$ Million by the following Product Segments: Endoscopes, and Visualization Equipment.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.

The report profiles 108 companies including many key and niche players such as Boston Scientific Corporation, Conmed Corporation, Ethicon Endo-Surgery, Inc., FujiFilm Corporation, Given Imaging Ltd., Hoya Corporation, Karl Storz GmbH & Co. KG, Medtronic, Inc., Olympus Corporation, Richard Wolf Medical Instruments Corporation, Smith & Nephew, and Stryker Corporation.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.